TOTAL: $599.3M Company (Location) Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (M) Investors; Placement Agents; Details Date Ablynx NV (Ghent, Belgium) Private placement of new shares 4.38S €31.5 ($40.9) Ablynx raised $40.9M through a private placement of new shares via an accelerated book-building procedure 3/4/13 Active Biotech AB (Lund, Sweden) Private placement 6S SEK270 ($42.6) Active Biotech raised $42.6M by issuing 6M shares to Investor AB 3/8/13

Type of Financing January February March Total ($M) Public offerings 2,305.0 195.5 748.3 3,248.8 Public/other 530.4 218.9 599.3 1,348.7 Private biotechs 194.7 135.6 73.3 403.5 Total ($M) 3,030.1 550.0 1,420.9 5,001.0 Notes: Public offerings = Initial, follow-on. Private biotechs = Financings of private firms. Public/other = Other financings of public companies, including loans, bridge financings, exercises of warrants, debt offerings, rights offerings, standard private placements, PIPE

I. COMMENCED TRADING IN MARCH Company (Symbol)# Date Filed Date Comm. Shares/ Units (M) Price Shares Out (M)@ Lead, Other Underwriters Gross (US$M) Post- Offering Market Cap (M)% INITIAL OFFERINGS Enanta Pharmaceuticals Inc. (Watertown, Mass.; ENTA)1 11/6/12 3/21/13 4.6S $14 17.44 J.P. Morgan Credit Suisse (co-lead) Leerink Swann JMP Securities $64.4 $244.16 Tetraphase Pharmaceuticals Inc. (Watertown, Mass.; TTPH)2 2/11/13 3/20/13 10.7S $7 19.9 Barclays BMO Capital Markets (co

The U.S. Court of Appeals for the First Circuit upheld a $142 million racketeering verdict against Pfizer and revived two similar civil cases filed by third-party payers asserting violations of the Racketeer Influenced and Corrupt Organizations (RICO) Act based on the company's off-label promotion of epilepsy drug Neurontin (gabapentin). The FDA released a draft guidance to help biosimilar sponsors request and be better prepared for formal meetings with the agency about product development. The

"Just because we have the Geron technology, the Geron cells and some of the Geron people, don't expect us to look, smell or taste like the old Geron. That got dismembered by the board." – Thomas Okarma, former Geron CEO, discussing the formation of BioTime Inc. subsidiary, Asterias Biotherapeutics Inc., which is purchasing Geron's embryonic stem cell assets "We're getting to a tipping point where nanomedicine is going from an interesting technology to something that's being viewed as a here-and

Financings Aquinox Pharmaceuticals Inc. raised $18 million from a Series C financing. Chimerix Inc. and Omthera Pharmaceuticals Inc. established terms for their initial public offerings. Revance Therapeutics Inc. raised $33 million in a Series E financing and converted $71 million in convertible debt into Series E preferred stock. Taris Biomedical Inc. said it raised an additional $12.5 million in a financing round. Deals BIND Therapeutics Inc. is collaborating with Pfizer Inc. on multiple

Personalized medicine offers the opportunity to transform healthcare by improving health outcomes and has the potential to make healthcare more cost-effective. This new era of healthcare has brought about significant changes in the drug discovery process – moving from a focus on discovering blockbuster drugs to creating targeted therapies, companion diagnostics and biomarkers. (See BioWorld Insight, Sept. 4, 2012.) Its potential to help relieve the burden on escalating healthcare costs has not

The environment for raising private capital continues to be challenging and, as a result, there has been a dramatic slowdown in the number of deals that have successfully been concluded. Worldwide, according to BioWorld Snapshots, private biotech companies developing therapeutics raised $403.5M in VC dollars in the first quarter of 2013, down a whopping 48 percent from the $775 million raised in the same period last year. BioWorld Insight writer Brian Orelli noted that among the VC funding of U

Biotech companies generated $5 billion in the first quarter of 2013, just 3 percent less than the $5.15 billion raised in the first quarter last year. The heavy lifting for the period was carried out by public companies, which were responsible for 65 percent of the total. The $3.25 billion raised by these public companies was 33 percent higher than the $2.5 billion total raised in the same period of 2012. The amount included almost $3 billion in follow-on financings with public companies seizing

Total: $62.3M Year to Date: $119.05M Company (Location) Partner (Location) Amt. (M) Details Date Genmab A/S (Copenhagen, Denmark) GlaxoSmithKline plc (London) DKK20 ($3.5) For the Japanese approval of Arzerra for use in patients with relapsed/refractory CD20-positive chronic lymphocytic leukemia 3/26/13 PolyTherics Ltd. (London) Celtic Pharma Holdings LP (London) ND For further progress on their hematology alliance to produce longer-acting versions of blood factor proteins 3/8/13 Receptos

Company Amount Raised Jounce Therapeutics Inc. $47M Labrys Biologics Inc. $31M Versartis Inc. $25M Gradalis Inc. $24M Marinus Pharmaceuticals Inc. $21M Elcelyx Therapeutics Inc. $20M Dezima Pharma BV $18.6M

Total: $73.29M Company Location Amt. (M) Details Date Calypso Biotech Geneva €2.5 ($3.24) Calypso, a Merck Serono spinoff, received $3.24M in seed funding 3/5/13 Carolus Therapeutics Inc. San Diego $2.25 Carolus received $2.25M in a debt facility from Square 1 Bank 3/6/13 Dezima Pharma BV Naarden, the Netherlands €14.2 ($18.6) Dezima raised $18.6M, including €9.8M in a Series A round, and a €4.4M loan from Dutch Ministry of Economic Affairs agency Agentschap NL 3/1/13 InteRNA Technologies BV

Company Amount Raised Ironwood Pharmaceuticals Inc. $175M OPKO Health Inc. $175M Mesoblast Ltd. $174.6M Pacira Pharmaceuticals Inc. $110M e-Therapeutics plc $62.66M